Cutler Group’s Fulcrum Therapeutics FULC Stock Holding History

Cutler Group’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,600	Closed	-$37K	–	5588
2021 Q3	$37K	Buy	+4,600	New	+$87.2K	﹤0.01%	2769

Other funds holding FULC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Cutler Group's FULC Position: Q1 2023 in Review

Cutler Group sold out of Fulcrum Therapeutics (FULC) in Q1 2023, closing a stake of 500 shares — an estimated $3K sold.

Cutler Group first reported a position in FULC in Q3 2021 and held it in 6 quarters. The position peaked at $25K in Q3 2021. 116 funds tracked by Wall St. Rank hold FULC as of Q1 2023.

Cutler Group reported no remaining Fulcrum Therapeutics position as of Q1 2023 after selling out during the quarter.
Cutler Group sold 500 Fulcrum Therapeutics shares in Q1 2023, an estimated $3K.
Cutler Group first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 6 quarters.
Cutler Group's Fulcrum Therapeutics position peaked at $25K in Q3 2021.
116 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.